{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T18:15:04Z","timestamp":1783793704438,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ijrobp.2024.04.009","type":"journal-article","created":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T01:45:05Z","timestamp":1713059105000},"page":"359-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety and Efficacy of Stereotactic Body Radiation Therapy for Ultra-central Thoracic Tumors: A Single Center Retrospective Review"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7811-177X","authenticated-orcid":false,"given":"George J.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrick","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humza","family":"Nusrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeevin","family":"Shahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee","family":"Ung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.04.009_bib0001","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): A phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0002","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S1470-2045(21)00401-0","article-title":"Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): Long-term results of a single-arm, prospective trial with prespecified comparison to surgery","volume":"22","author":"Chang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0003","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): Extended long-term outcomes","volume":"114","author":"Harrow","year":"2022","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0004","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0005","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamaoncol.2018.1258","article-title":"Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0006","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2018.1251","article-title":"Stereotactic body radiation therapy for operable early-stage lung cancer: Findings from the NRG oncology RTOG 0618 trial","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0007","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","article-title":"Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer","volume":"103","author":"Videtic","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0008","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0009","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/JTO.0000000000000453","article-title":"Stereotactic ablative radiotherapy for centrally located early stage non\u2013small-cell lung cancer: What we have learned","volume":"10","author":"Chang","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0010","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jtho.2019.04.018","article-title":"Safety and effectiveness of stereotactic ablative radiotherapy for ultra-central lung lesions: A systematic review","volume":"14","author":"Chen","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0011","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.21037\/jtd.2020.03.112","article-title":"Stereotactic ablative radiotherapy for malignant mediastinal and hilar lymphadenopathy: A systematic review","volume":"12","author":"Tjong","year":"2020","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0012","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ijrobp.2020.10.004","article-title":"Stereotactic body radiation therapy for mediastinal and hilar lymph node metastases","volume":"109","author":"Shahi","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0013","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2016"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0014","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed October 26, 2022."},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0015","unstructured":"National Cancer Institute. NCI guidelines for investigators: Adverse event reporting requirements for DCTD (CTEP and CIP) and DCP INDs and IDEs. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/aeguidelines.pdf. Accessed October 26, 2022."},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0016","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non\u2013small-cell lung cancer: NRG oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijrobp.2023.03.056","article-title":"Some like it hot: The value of dose and hot spots in lung stereotactic body radiation therapy","volume":"117","author":"Owen","year":"2023","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0018","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-Trial\u2014A prospective nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0019","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.3390\/cancers14235908","article-title":"Survival and prognostic factors of ultra-central tumors treated with stereotactic body radiotherapy","volume":"14","author":"Salvestrini","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0020","article-title":"Safety and efficacy of stereotactic ablative radiotherapy for ultra-central lung cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0021","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/0284186X.2021.1942545","article-title":"Ultra-central lung tumors: Safety and efficacy of protracted stereotactic body radiotherapy","volume":"60","author":"Lodeweges","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0022","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210533","article-title":"Toxicity and efficacy of stereotactic body radiotherapy for ultra-central lung tumours: A single institution real life experience","volume":"95","author":"Guillaume","year":"2022","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0023","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.radonc.2021.03.001","article-title":"Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity","volume":"158","author":"Breen","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0024","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/j.prro.2021.03.005","article-title":"Organ at risk dose constraints in SABR: A systematic review of active clinical trials","volume":"11","author":"Gerhard","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0025","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ijrobp.2023.06.246","article-title":"Expanded HILUS trial: A pooled analysis of risk factors for toxicity from stereotactic body radiation therapy of central and ultracentral lung tumors","volume":"117","author":"Lindberg","year":"2023","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0026","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","article-title":"SUNSET: Stereotactic radiation for ultracentral non\u2013small-cell lung cancer\u2014A safety and efficacy trial","volume":"19","author":"Giuliani","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0027","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.10.049","article-title":"Stereotactic radiation for ultra-central non-small cell lung cancer: A safety and efficacy trial (SUNSET)","volume":"118","author":"Giuliani","year":"2024","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107281","article-title":"Stereotactic body radiotherapy for ultra-central lung tumors: A systematic review and meta-analysis and International Stereotactic Radiosurgery Society practice guidelines","volume":"182","author":"Yan","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0029","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.prro.2015.09.012","article-title":"Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree","volume":"6","author":"Haseltine","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0030","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jamaoncol.2019.0205","article-title":"Analysis of toxic effects with antiangiogenic agents plus stereotactic body radiation in ultracentral lung tumors","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0031","article-title":"Safety and tolerability of metastasis-directed radiation therapy in the era of evolving systemic, immune, and targeted therapies","volume":"7","author":"Guimond","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0032","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3","article-title":"Younger women with breast carcinoma have a poorer prognosis than older women","volume":"77","author":"Chung","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0033","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s00268-004-7306-7","article-title":"Do young colon cancer patients have worse outcomes?","volume":"28","author":"O'Connell","year":"2004","journal-title":"World J Surg"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0034","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160251","article-title":"Stereotactic body radiotherapy for oligoprogressive cancer","volume":"89","author":"Cheung","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0035","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","article-title":"Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: A phase 2 prospective multicenter study","volume":"80","author":"Cheung","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0036","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR -mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0037","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0038","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4143\/crt.2022.1460","article-title":"Top ten lessons learned from trials in oligometastatic cancers","volume":"55","author":"Tan","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0039","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 4\u201310 oligometastatic tumors (SABR-COMET-10): Study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0040","doi-asserted-by":"crossref","first-page":"6045","DOI":"10.21037\/apm-20-847","article-title":"A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions","volume":"10","author":"Li","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0041","unstructured":"Canadian Cancer Trials Group. Local ablative therapy for hormone sensitive oligometastatic prostate cancer (PLATON). Accessed September 25, 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03784755"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0042","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: An open-label, randomised, phase 2 trial","volume":"402","author":"Chang","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0043","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/JTO.0b013e318219aac5","article-title":"Radiological changes after stereotactic radiotherapy for stage I lung cancer","volume":"6","author":"Dahele","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0044","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1016\/j.ijrobp.2022.07.1510","article-title":"Assessing treatment response after lung SABR: An evaluation of the predictive value of RECIST criteria","volume":"114","author":"Gulstene","year":"2022","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109976","article-title":"What is the predictive value of RECIST criteria following stereotactic lung radiation?","volume":"190","author":"Gulstene","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.009_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109848","article-title":"Ten years outcomes after SABR in central and ultracentral primary lung tumors","volume":"188","author":"Tekatli","year":"2023","journal-title":"Radiother Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162400508X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162400508X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T05:04:13Z","timestamp":1737781453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162400508X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S036030162400508X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.04.009","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Stereotactic Body Radiation Therapy for Ultra-central Thoracic Tumors: A Single Center Retrospective Review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}